Use our guide to learn which trials are right for you!

Prospective, multicenter, case-cohort study.To identify potential risk factors associated
with the occurrence of erosion due to implantation of the AMPLATZER™ Septal Occluder (ASO.)

This study will enroll 8000 subjects. The sub-cohort will consist of 160 (2%) subjects,
randomly selected from the full cohort. The analysis population will consist of all subjects
in the sub-cohort, combined with all subjects with erosion events who are not in the
sub-cohort. A detailed assessment of risk factors will be conducted on the subjects in this
analysis population.

Inclusion Criteria:

To participate in this clinical investigation, the patient must meet all of the following
inclusion criteria:

1. Patient indicated for ASD closure who has echocardiographic evidence of ostium
secundum atrial septal defect and clinical evidence of right ventricular volume
overload (such as, 1.5:1 degree of left-to-right shunt or RV enlargement) and is
implanted with the ASO device Note: This does not include the indication for closure
of a fenestration following a fenestrated Fontan procedure

2. Patient is willing and able to complete the follow-up requirements of this study